Benzinga·2025-12-23 17:06Core Insights - Lexaria Bioscience Corp. has successfully completed its Phase 1b, 12-week chronic study GLP-1-H24-4 in Australia, demonstrating superiority in reducing side effects compared to Novo Nordisk's Rybelsus [1][2] Study Results - The study achieved its primary endpoint, showing that all four DehydraTECH (DHT) formulations were safe and well tolerated, with lower rates of treatment-emergent adverse events (AEs) compared to Rybelsus [3] - DHT-semaglutide showed a 47.9% reduction in total AEs and a 54.9% reduction in gastrointestinal AEs compared to Rybelsus [4] - The reduction in HbA1c levels was comparable between DHT-semaglutide and Rybelsus, but bodyweight reduction was better in the Rybelsus arm at both week 12 and week 16 evaluations [5] Future Development - Lexaria plans to further develop the DHT-semaglutide formulation and is considering incorporating salcaprozate sodium (SNAC) in future studies [6] - The company is evaluating options for follow-on human clinical testing of a DehydraTECH + SNAC + semaglutide formulation against Rybelsus [6][7] Market Reaction - Following the news, Lexaria's stock (LEXX) experienced a decline of 7.42%, trading at $0.63 [8]